Latest News about Biogen Inc
Recent news which mentions Biogen Inc
Stocks making the biggest moves midday: DoorDash, Biogen, T. Rowe Price, Crocs and more
January 12, 2022
From CNBC.com News
Investing Club: What Jim Cramer is watching Wednesday — Did Powell outwit the critics?
January 12, 2022
From CNBC.com News
From CNBC.com News
From CNBC.com News
Government may scale back Medicare Part B premium increase
January 10, 2022
From CNBC.com News
Why Biogen's Alzheimer's drug Aduhelm is so controversial
January 04, 2022
From CNBC.com News
From CNBC.com News
From CNBC.com News
Jim Cramer's stock market winners and losers for 2021
December 23, 2021
From CNBC.com News
From CNBC.com News
From CNBC.com News
Stocks making the biggest moves premarket: Moderna, Royal Caribbean, Cerner and others
December 20, 2021
From CNBC.com News
Here's how one drug can be responsible for 50% of the hike in Medicare's Part B premiums
December 12, 2021
From CNBC.com News
Under-the-surface market checks suggest sell-off worse than it appears. Why that's a good thing
December 07, 2021
From CNBC.com News
Investors could get 'a gift' if this S&P stock continues its pullback, trader says
December 01, 2021
From CNBC.com News
From CNBC.com News
From CNBC.com News
Stocks making the biggest moves before the bell: Biogen, Novavax, Netflix, Verizon & more
October 20, 2021
From CNBC.com News
From CNBC.com News
From CNBC.com News
Stocks making the biggest moves in the premarket: Zillow, Revance Therapeutics, Albertsons and more
October 18, 2021
From CNBC.com News
Two beaten-down S&P 500 stocks could be due for a rebound, traders say
September 23, 2021
From CNBC.com News
From CNBC.com News
What to watch today: Dow set to jump after snapping four-day losing streak
September 23, 2021
From CNBC.com News
Stocks making the biggest moves premarket: Darden Restaurants, BlackBerry, Salesforce and others
September 23, 2021
From CNBC.com News
One lagging Nasdaq 100 stock looks 'ridiculously cheap,' trader says. Why it may be time to buy
August 24, 2021
From CNBC.com News
From CNBC.com News
Biogen's controversial Alzheimer’s drug generates $2 million in first few weeks after approval
July 22, 2021
From CNBC.com News
From CNBC.com News
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
|
|
|
|
|
|